Evgen Pharma plc – LSE:EVG.L

Evgen Pharma stock price today

GBP 5.15
+4.4
+586.67%
Financial Health
0
1
2
3
4
5
6
7
8
9

Evgen Pharma stock price monthly change

-6.25%
month

Evgen Pharma stock price quarterly change

-28.57%
quarter

Evgen Pharma stock price yearly change

-79.73%
year

Evgen Pharma key metrics

Market Cap
 3.49M
Enterprise value
 N/A
P/E
 -3.65
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 0.49
PEG ratio
 1.74
EPS
 -0.02
Revenue
 N/A
EBITDA
 -7.37M
Income
 -6.10M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Evgen Pharma stock price history

Evgen Pharma stock forecast

Evgen Pharma financial statements

Profit Margin

Evgen Pharma plc (LSE:EVG.L): Profit margin
Dec 2021 0 -603K
Sep 2022 0 -2.14M
Mar 2023 442K -1.89M -428.51%
Sep 2023 396K -1.45M -368.43%
EVG.L income statement history

Evgen Pharma Financials Estimate

Evgen Pharma plc (LSE:EVG.L): Analyst Estimates
2026 186.46K -1.09M -589.67%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Evgen Pharma plc (LSE:EVG.L): Debt to assets
Jun 2022 7571000 434K 5.73%
Sep 2022 7571000 434K 5.73%
Dec 2022 6174000 833K 13.49%
Sep 2023 4350000 415K 9.54%
EVG.L balance sheet history

Cash Flow

Evgen Pharma plc (LSE:EVG.L): Cash Flow
Sep 2021 -1.53M -4K 0
Sep 2022 -1.85M -1K 0
Mar 2023 -2.17M 4.52M 0
Sep 2023 -1.27M 0 0
EVG.L cash flow history

Evgen Pharma alternative data

Evgen Pharma
Employees

Evgen Pharma plc (LSE:EVG.L): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 10
Dec 2023 10
Jan 2024 10
Feb 2024 10
Apr 2024 10
May 2024 10
Jun 2024 10
Jul 2024 10

Evgen Pharma other data

Evgen Pharma
Executives

Insider Compensation
Dr. Huw Jones (1960) Chief Executive Officer
 $224,400
Mr. Richard Anthony Moulson (1962) Chief Financial Officer & Executive Director
 $107,280

Frequently Asked Questions (FAQ)

  • What's the price of Evgen Pharma stock today?

    One share of Evgen Pharma stock can currently be purchased for approximately $5.15.

  • When is Evgen Pharma's next earnings date?

    Unfortunately, Evgen Pharma's (EVG.L) next earnings date is currently unknown.

  • Does Evgen Pharma pay dividends?

    No, Evgen Pharma does not pay dividends.

  • How much money does Evgen Pharma make?

    Evgen Pharma has a market capitalization of 3.49M.

  • What is Evgen Pharma's stock symbol?

    Evgen Pharma plc is traded on the LSE under the ticker symbol "EVG.L".

  • What is Evgen Pharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Evgen Pharma?

    Shares of Evgen Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Evgen Pharma's key executives?

    Evgen Pharma's management team includes the following people:

    • Dr. Huw Jones Chief Executive Officer(age: 65, pay: $224,400)
    • Mr. Richard Anthony Moulson Chief Financial Officer & Executive Director(age: 63, pay: $107,280)

  • How many employees does Evgen Pharma have?

    As Jul 2024, Evgen Pharma employs 10 workers.

  • When Evgen Pharma went public?

    Evgen Pharma plc is publicly traded company for more then 9 years since IPO on 21 Oct 2015.

  • What is Evgen Pharma's official website?

    The official website for Evgen Pharma is evgen.com.

  • How can i contact Evgen Pharma?

    Evgen Pharma can be reached via phone at +44 1625 466591.

Evgen Pharma company profile:

Evgen Pharma plc

evgen.com
Exchange:

LSE

Full time employees:

10

Industry:

Biotechnology

Sector:

Healthcare

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

+44 1625 466591
Alderley Park, Block 24
Nether Alderley, SK10 4TG

:
ISIN: GB00BSVYN304
: